Lumida
/MET
⌘K
MetLife Inc

MetLife Inc

MET
$97.14USD+0.37%+0.36 today

MARKET CAP

61.7B

P/E (TTM)

9.9x

FWD P/E

9.1x

DAY RANGE

$96 – $98

52W RANGE

$67
$101

AI Summary

Stalk
Buy NowMedium

MET remains in a Stage 2 advancing phase with bullish medium- and long-term biases confirmed by rising EMAs and successive higher highs and lows. Price is holding just above the rising 9- and 20-day EMAs near the $95–96 support zone, with no signs of exhaustion and RSI in neutral territory. Short-term conditions favor immediate participation at dynamic support, targeting a continuation toward new highs, while a breakdown below EMAs would warrant deferment.

  • Q2 adjusted earnings $1.6B up 15% YoY, EPS $1.09 (+20%)
  • Adjusted ROE reached 17%, underscoring strong profitability
  • Negative growth and revision factors imply turnover challenges
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$68.7B$68.8B$66.9B$71.0B$77.1B
YoY %+1.3%+0.1%-2.7%+6.1%+8.6%
P / Sales0.8x0.8x0.8x0.8x0.7x
EV / Sales10.6x9.8x10.3x9.7x9.7x
Gross Profit, Adj.$25.6B$19.3B$22.3B$26.3B$27.4B
YoY %-3.0%-24.7%+15.8%+17.7%+4.2%
Margin %37.2%28.0%33.4%37.0%35.5%
EV / Gross Profit28.4x34.8x30.8x26.2x27.3x
EBITDA, Adj.$6.9B$2.5B$509.0M$3.5B$2.9B
YoY %+3.0%-64.1%-79.5%+589.4%-16.9%
Margin %10.1%3.6%0.8%4.9%3.8%
EV / EBITDA104.8x270.1x1351.7x196.0x256.3x
EBIT$8.5B$6.4B$2.2B$5.6B$4.7B
YoY %+23.0%-25.3%-66.0%+160.0%-17.1%
Margin %12.4%9.3%3.2%7.9%6.0%
EV / EBIT85.3x105.5x318.2x122.4x160.3x
Net Income$6.7B$5.1B$1.4B$4.2B$3.2B
YoY %+28.2%-23.4%-72.9%+206.2%-24.9%
Net Margin9.7%7.4%2.1%6.0%4.1%
EPS (GAAP)$7.65$6.30$1.81$5.94$4.71
YoY %+34.7%-17.6%-71.3%+228.2%-20.7%